MONISTAT 7
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MONISTAT 7 (MONISTAT 7).
Miconazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, reducing ergosterol synthesis and disrupting fungal cell membrane integrity.
| Metabolism | Minimal systemic absorption after vaginal application; any absorbed miconazole is extensively metabolized in the liver via oxidative pathways and excreted in feces and urine. |
| Excretion | Primarily via feces (approximately 87-93% of dose) as unchanged drug and metabolites; renal excretion negligible (<1%). |
| Half-life | Terminal elimination half-life is approximately 24-30 hours following intravaginal administration; clinical significance: supports once-daily dosing. |
| Protein binding | Approximately 88-90% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Apparent Vd is approximately 0.25-0.35 L/kg; indicates extensive tissue distribution with high local concentrations at vaginal mucosa. |
| Bioavailability | Intravaginal: Approximately 5-10% systemic absorption of the administered dose; negligible when applied topically. |
| Onset of Action | Intravaginal: Relief of symptoms (itching, discharge) typically begins within 24-72 hours after first dose. |
| Duration of Action | Therapeutic concentrations persist locally for at least 72 hours after a single dose; clinical cure rate >80% after 7-day regimen. |
| Molecular Weight | 416.13 |
Intravaginal administration of 100 mg miconazole nitrate suppository once daily at bedtime for 7 days.
| Dosage form | SUPPOSITORY |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No specific guidelines; use with caution in severe hepatic impairment due to limited data. |
| Pediatric use | Not recommended for children under 12 years; for adolescents 12 years and older, same adult dose. |
| Geriatric use | No dose adjustment needed; consider potential for reduced vaginal mucosal integrity. |
| 1st trimester | Topical miconazole is generally considered safe in pregnancy based on epidemiological data; however, systemic absorption is minimal. Use only if clearly needed. |
| 2nd trimester | No known fetal risk; minimal systemic absorption. Considered safe for use. |
| 3rd trimester | No known fetal risk; minimal systemic absorption. Considered safe for use. |
Clinical note
Comprehensive clinical and safety monograph for MONISTAT 7 (MONISTAT 7).
| Placental transfer | Minimal; miconazole has low systemic absorption after topical application, and placental transfer is expected to be negligible at therapeutic doses. |
| Breastfeeding | Topical miconazole has minimal systemic absorption and is unlikely to affect the nursing infant. The manufacturer recommends caution, but clinical data support its use during breastfeeding when applied topically. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to miconazole or any component of the formulation
| Precautions | If sensitization or irritation occurs, discontinue use. Patients with known hypersensitivity should avoid use. Discontinue if symptoms persist or recur within 2 months. |
| Food/Dietary | No known food interactions with intravaginal miconazole. No dietary restrictions required. |
| Clinical Pearls | MONISTAT 7 contains miconazole nitrate 100 mg per suppository or 2% cream, used intravaginally for vulvovaginal candidiasis. Ensure patient completes full 7-day course even if symptoms resolve. Avoid concurrent use of condoms or diaphragms as the product base may damage latex. Consider alternative treatment in pregnant patients; though generally safe, prolonged use is not recommended. Do not use if patient has fever, lower abdominal pain, or malodorous discharge—these suggest more serious infection. For recurrent infections (≥4 episodes/year), consider culture confirmation and longer treatment or maintenance therapy. |
Loading safety data…
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | FDA Pregnancy Category C. No evidence of teratogenicity in animal studies at intravaginal doses up to 200 mg/kg/day (maternal toxic doses). No adequate human studies; topical absorption minimal. First trimester: theoretical risk minimal, but avoid if possible; second/third trimester: considered safe for vaginal candidiasis. |
| Fetal Monitoring | No specific monitoring required. Monitor for local irritation or allergic reaction. In pregnancy, assess for recurrent infection or treatment failure. |
| Fertility Effects | No known adverse effects on fertility in animal or human studies. Not indicated for contraception. |
| Patient Advice | Use one suppository or applicatorful of cream at bedtime for 7 consecutive nights. · Do not use tampons, douches, or have sexual intercourse during treatment. · The product may damage latex condoms and diaphragms; wait 72 hours after last dose before relying on these for contraception. · Itching, burning, or irritation may worsen initially; if symptoms persist beyond 7 days or if fever, chills, or abnormal discharge occur, contact your healthcare provider. · Complete the full course even if menstruation begins or symptoms improve. |